BCRX · NASDAQ · Biotechnology

BioCryst Pharmaceuticals (BCRX)

Commercializes oral ORLADEYO and develops injectable navenibart for hereditary angioedema.

$8.78
After hours+0.01 (+0.11%)
At close$8.77(+0.11%)